
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna's projected product sales are expected to grow from $1.73 billion in 2025 to $2.15 billion in 2026, reflecting strong commercial potential and revenue growth prospects. The company has strengthened its balance sheet through a $1.5 billion debt deal, which enhances its financial flexibility to manage uncertainties and capitalize on future opportunities. Furthermore, improvements in manufacturing efficiency are anticipated to re-expand gross margins by 10% over the next three years, signaling a recovery and potential profitability enhancement following previous compressions.
Bears say
Moderna's revenue from COVID-19 vaccine sales has seen a significant decline, dropping from $18 billion in 2022 to $6.7 billion in 2023, with further downward adjustments anticipated in future revenue projections due to waning vaccination rates and increased competition from other vaccines. The firm faces additional challenges with its other pipeline programs, particularly concerning the mRESVIA vaccine for RSV, which is hindered by competition from existing vaccines, and slow progress in its therapeutic development outside of respiratory indications. As a result of these factors, long-term revenue expectations have been substantially lowered, reflecting an overall negative outlook for the company's financial growth trajectory.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares